In comparison with enalapril, an angiotensin-converting enzyme (ACE) inhibitor, it has a better effect in reducing the incidence rate and mortality rate of heart failure patients with decreased ejection fraction [40,41,42]. This evidence concerns the gene ACE and heart failure.